Skin Cancers | Clinical

Roundtable Discussion: Savvides Analyzes Role of Hedgehog Inhibitors and Immunotherapy in BCC

November 29, 2022

During a Targeted Oncology case-based roundtable event, Panayiotis S. Savvides, MD, PhD, MPH, discussed with participants their experiences using hedgehog pathway inhibitors and immunotherapy for patients with basal cell carcinoma.

Tumor Infiltrating Lymphocyte Data Signal Promise for New Options to Treat Advanced Melanoma

November 16, 2022

In an interview with Targeted Oncology, Ryan J. Sullivan, MD, discussed the history of tumor infiltrating lymphocyte therapy, how new data may lead to approved agents in the future, and other ways tumor infiltrating lymphocytes may be used in advanced melanoma.

IO Before BRAK/MEK Inhibition Is the Ideal Treatment Sequence for BRAF-Mutant Melanoma

October 11, 2022

Data from the DREAMseq trial have answered a lingering question of how to sequence therapy for patients with advanced BRAF-mutant melanoma. This research supports immunotherapy in the first-line setting, followed by BRAK/MEK inhibitors.